To strengthen Richter’s contribution to SDG 5 further, we believe the group could go beyond offering the above solutions and address women’s empowerment from an operational standpoint further.
Thanks to IVF and other treatments, fertility is increasing in the over 40s age category, helping women who have postponed motherhood due to financial constraints or the need to advance and consolidate their careers to fulfil their dream of parenthood.
Declining birth rates have led to ageing populations in most developed countries, which is a demographic problem. Used by over 500,000 women 6 since its launch in 2014, Bemfola now accounts for 4% of Richter’s total sales. On the other side of the coin, Richter helps women with fertility issues to increase their chances of getting pregnant with its fertility drug Bemfola. 4 Richter is involved in sexual and reproductive health information and education programmes: from 2015, Richter, in cooperation with ÄGGF, supports the School of Contraception and Lady’s Talk programs in the CIS region 5, with the aim of decreasing unwanted pregnancies and abortion among adolescents. Family planning is linked to positive outcomes including a decrease in the ratio of teenage mothers, lower abortion rates (including unsafe abortions), higher female education rates and overall women’s empowerment.ĭata shows that educational programmes focused on sexuality, body change during puberty and availability of contraception significantly decrease the number of abortions. Some of the firm’s products are used in national family planning programmes such as those recently sponsored by the ministries of health in Moldova and Uzbekistan. According to data from health information company IQVIA, approximately 2.2 million women use Richter’s oral contraceptive, with around another 135,000 using its intrauterine contraceptive delivery system Levosert. With 23% of its 2020 revenues coming from the sale of oral contraceptives, birth control and family planning are very important for Richter too. They also often face major disruption to their own lives since caring for the patient requires significant time and dedication. The physical, social and mental burden is felt not only by sufferers but also by their families: research conducted by Richter in four eastern European countries found that family members struggle with a lack of information. Schizophrenia is a chronic psychiatric disorder that affects about 1% of the population, or an estimated 5 million people in the EU alone. 2 Most of its awareness campaigns are focused on unmet needs in schizophrenia treatment. In 2020 approximately 25,000 physicians and other health care practitioners engaged in disease awareness campaigns organised by Richter in CEMEA. Use for this purpose is in Phase III trials approval would add substantial upside to the stock.Īs well as selling medicines, Richter runs social research studies and mental health awareness campaigns. In addition to these approved indications, cariprazine has potential to be used for the treatment of major depressive disorder (MDD). 1 A further 30,000 patients were being prescribed the drug in Europe, where it is approved to treat schizophrenia in adults.
According to the company, at the end of 2020 around 130,000 patients were estimated to be on cariprazine in the US, where it is approved to treat bipolar I disorder. Growth is due to maturing conditions for its drug, cariprazine (sold under the brand name Vraylar in the US and as Reagila in Europe) as well as increasing awareness of mental health in general. Drugs to treat mental health issues are a growing source of Richter’s revenue: the company derived €320 million, or 20%, of its overall 2020 sales, from drugs treating mental health issues.
0 kommentar(er)
